Nanosonics Posts 17% Revenue Growth and 72% Profit Jump in FY25

Strong Financial Performance Anchored by Recurring Revenue

Nanosonics Limited has reported a solid financial year ending June 2025, with total revenue climbing 17% to $198.6 million. This growth was largely driven by a 20% increase in recurring revenue from consumables and services, which now represent the bulk of the company’s income at $146.1 million. Capital revenue from device sales and upgrades also rose 9% to $52.5 million, reflecting steady expansion of the installed base to 37,000 trophon units globally.

Profitability metrics were equally impressive, with earnings before interest and tax (EBIT) nearly doubling to $17.8 million and profit before tax soaring 72% to $22.3 million. These gains underscore improved operating leverage and disciplined expense management, even as the company continued investing in research and development and operational infrastructure.

Next-Generation Trophon Innovations Drive Market Leadership

Central to Nanosonics’ growth story is the launch of its next-generation ultrasound probe reprocessing technology, trophon3, alongside the trophon2 Plus software upgrade. These innovations offer over 40% faster processing times and enhanced digital integration, including advanced traceability through DICOM imaging systems. The upgrades are designed to expand the installed base and encourage existing customers to adopt new software capabilities, thereby fueling recurring revenue streams.

The company’s strategic focus on both new device sales and software upgrades is expected to sustain momentum in key markets such as North America, Europe, and APAC. With approximately 10,000 first-generation devices eligible for upgrade, the opportunity for growth remains significant.

CORIS Advances Towards Commercialisation

Another highlight was the US FDA clearance of CORIS, Nanosonics’ automated flexible endoscope cleaning system. This milestone paves the way for expanded regulatory submissions and a Controlled Market Release (CMR) planned for FY26 in Europe, Australia, and eventually the US. The CMR will allow real-world testing and feedback before full commercial rollout, positioning CORIS as a potential new growth engine addressing critical infection prevention challenges.

Investment in manufacturing capacity also progressed, with expansions in the Indianapolis facility to support consumables production for both trophon and CORIS. The company plans to relocate its headquarters and manufacturing operations in Sydney by the second half of FY27, signaling long-term commitment to operational scalability.

Sustainability and Outlook

On the sustainability front, Nanosonics achieved a key milestone by sourcing 100% renewable energy for its Australian and US operations, significantly reducing its carbon footprint. This aligns with broader industry trends towards environmentally responsible healthcare solutions.

Looking ahead, Nanosonics projects revenue growth of 8-12% for FY26, with gross margins expected between 75-77% despite ongoing US tariffs. The company remains cautious about macroeconomic uncertainties but confident that its innovation pipeline and expanding installed base will support continued growth and shareholder value creation.